VIR - Vir begins dosing in mid-stage study of VIR-2218 VIR-3434 for hepatitis D virus
- Vir Biotechnology ( NASDAQ: VIR ) said the first patient was dosed in a phase 2 trial of VIR-2218 and VIR-3434 as monotherapy and in combination to treat people with chronic hepatitis D virus (HDV), which occurs as a simultaneous co-infection or super-infection with hepatitis B virus (HBV).
- The study, dubbed SOLSTICE, will evaluate VIR-2218 and VIR-3434 in adult patients aged 18 years to 69 years with chronic HDV infection receiving nucleotide reverse transcriptase inhibitor therapy, the company said in a Sept. 22 press release.
- Based on the group, people will receive multiple doses of VIR-2218 and VIR-3434 as either monotherapy or in combination given as a subcutaneous injection for up to 88 weeks.
For further details see:
Vir begins dosing in mid-stage study of VIR-2218, VIR-3434 for hepatitis D virus